GeoVax Announces Initiation of Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia
20 juil. 2023 09h00 HE
|
GeoVax, Inc.
Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing...
GeoVax Presents Gedeptin® Clinical Data at the AACR-AHNS Head and Neck Cancer Conference
10 juil. 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, July 10, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Announces Gedeptin® Presentation at the AACR-AHNS Head and Neck Cancer Conference
28 juin 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, June 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Universal Coronavirus Vaccine Design & Development Approach Published in Vaccine Insights
27 juin 2023 10h15 HE
|
GeoVax, Inc.
Spotlight Content on Pandemic Preparedness: Getting Ready for the Next “Disease X” ATLANTA, GA, June 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax Partners With ABL to Advance cGMP Production of Vaccine Candidates
31 mai 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, May 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax to Participate in Upcoming Industry Meetings
25 mai 2023 09h00 HE
|
GeoVax, Inc.
Management to participate in 2023 ASCO Annual Meeting and 2023 BIO International Convention ATLANTA, GA, May 25, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a...
GeoVax’s Next-Generation COVID-19 Vaccine Shows High Immunogenicity in Immunocompromised Patients
24 mai 2023 08h00 HE
|
GeoVax, Inc.
New and Unpublished Data from Phase 2 Open-Label Safety Study ofGEO-CM04S1 Presented at Two Recent Scientific Meetings ATLANTA, GA, May 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Next-Generation COVID-19 Vaccine Data to be Presented at Two Upcoming Scientific Meetings
15 mai 2023 09h00 HE
|
GeoVax, Inc.
Presentations to Include New and Unpublished Data from Phase 2 Open-Label Safety Study of GEO-CM04S1 ATLANTA, GA, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs,...
GeoVax Labs to Participate in A.G.P.’s Virtual Healthcare Conference
09 mai 2023 09h00 HE
|
GeoVax, Inc.
ATLANTA, GA, May 09, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
GeoVax Reports 2023 First Quarter Financial Results and Provides Corporate Update
04 mai 2023 16h00 HE
|
GeoVax, Inc.
Cancer Gene Therapy Program and Next-Generation COVID-19 VaccineAdvancing in Phase 2 Clinical Trials Company to Host Conference Call and Webcast Today at 4:30...